Scientists have developed a nasal "molecular shield" that disarms pollen, blocking allergic reactions fast without the use of ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

A new study found that almost all plans in 40 states and Washington, DC covered at least one form of the opioid overdose ...

Xlear, a company based in American Fork, is suing the FTC, fighting regulations restricting its ability to market hygiene ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

The FTC sued Xlear after it marketed its spray as a covid preventative. The Trump administration dropped the suit, but the ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Dosing began at Weill Cornell Medical Center in a Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS.

SAN FRANCISCO — Both dyspnea and respiratory drive went down with vs. without nasal high-flow therapy in orally intubated patients, according to research presented at the American Thoracic ...